TORONTO, Aug. 2 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced an agreement with JUSTE S.A.Q.F. ("JUSTE"), a leading supplier of
in-vitro diagnostic technologies, medical devices, and pharmaceuticals in
Spain, to sell and distribute Spectral's EAA(TM) Endotoxin Activity Assay.
Spectral has been actively developing a strong network of top-tier
distributor relationships on a regional basis in Europe, where the potential
for early growth of EAA(TM) sales is strong. JUSTE, which has an extensive
network of sales and support in Spain, and Spectral will work jointly to
maximize sales of the EAA(TM). JUSTE has initially placed a significant order
for tests and instrumentation to ensure rapid introduction of the product into
the Spanish market.
"We are very pleased to announce this new relationship with JUSTE,"
stated Dr. Paul Walker, President and CEO of Spectral. "Their dominant
presence in Spain will put EAA(TM) in the best possible position to capture
this important market. Spectral believes that working with strong local
distributors that have close ties to clinicians and hospitals will
significantly increase the rate of the uptake of EAA(TM)."
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Currently products include Spectral's rapid West Nile Virus (WNV) assay and
its FDA approved rapid diagnostic for sepsis (the Endotoxin Activity Assay) as
well as a range of other biological reagents. Spectral's common shares are
listed in the Toronto Stock Exchange under the symbol "SDI".
JUSTE, S.A.Q.F. is a company which researches, develops and distributes
pharmaceutical, diagnostic and medical device products. Its main business
areas are the distribution and commercialization of drugs (both for hospital
and prescription use) and contrast media agents. JUSTE, through Juste
International subsidaries, is present in Central America, as well as in
Argentina, Mexico and Brazil via Justesa Imagen affiliates. Revenues of Juste
Group in 2005 were 121 Million Euros.
Information in this news release that is not current or historically
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, the future outlook
of Spectral and anticipated events or results are assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected.
%SEDAR: 00002006E
